News

Medication errors and patient falls in COVID-19-positive and non-COVID-19 patients highlight the impact of hospital workload on patient safety.

Alveo Technologies announced it entered into an agreement with the Centers for Disease Control and Prevention (CDC) to create a test to help in offering this capability in case there is a need for widespread diagnostics.

Participants who used fentanyl were 1.64 times more likely to experience HCV seroconversion compared to those who did not.

Sakoulas offered his insights for when he considers discharging patients and strategies to avoid readmission.

17 randomized controlled trials involving 4,148 patients assessed the efficacy of various treatments, finding that fecal microbiota transplantation via the lower gastrointestinal route was the most effective.

The country’s largest fecal distributor, OpenBiome, could be prevented from offering the product next year if the FDA does not approve the product used for fecal microbiota transplants to treat fulminant C difficile.

Results suggest a shorter treatment duration could reduce costs and improve access in low- and middle-income countries.

In this conversation, Sakoulas discusses a specific therapy indicated for CABP.

George Sakoulas, MD, offered clinical considerations for treatment selection.

Chad Costley, MD, MPH, discussed the platform's ability to respond to emerging respiratory diseases and the challenges in advancing mucosal vaccine development for health preparedness.

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.

Chad Costley, MD, MBA, provided an update on BlueWillow Biologics' NanoVax intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.

Affected products include Taiwan Enoki mushrooms, select soft-ripened cheeses, and Autumn Turkey Sandwiches.

George Sakoulas, MD, provided commentary on challenging patients with comorbidities such as COPD, structural lung disease, asthma, and other health issues.

Findings from the CAPELLA study reveal virologic suppression and a safety profile for multidrug-resistant HIV-1.

Investigators propose limiting initial use of antibiotics for group A streptococcal pharyngitis in children after finding placebo noninferior in reducing symptoms.

The combination of the antiviral agents islatravir and lenacapavir demonstrates both efficacy and safety, leading to advancement into Phase 3 trials.

New therapeutics offer some hope in this emerging market.

From improving infection control and antibiotic stewardship, identifying RT 027 as a risk factor for vancomycin resistance in C diff, developing a universal flu vaccine, better management for drug-resistant pathogens, and more.

In a world heavily focused on therapeutic options for multidrug-resistant gram-negative organisms, the emergence of antimicrobial resistance among enterococci is often an under-recognized risk.

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.

A five-year study highlights high virologic suppression and well-tolerated treatment in black patients.

Current guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.

A study of carbapenemase-producing organisms found similar rates of infections, highlighting treatment challenges, the role of rapid diagnostics, and surveillance on antimicrobial stewardship due to high mortality rates.

Survey data show pharmacists are integral to HCV screening and treatment across healthcare settings, highlighting their contributions to HCV elimination efforts.

Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.

Led by Shruti K. Gohil, MD, MPH, the trials examined how computerized physician order entry prompts can reduce the use of extended-spectrum antibiotics in hospitalized patients while maintaining patient safety.

ActivePure’s Deborah Birx, MD, and Amy Carenza, BBA, discuss their study showing a 99% reduction in fungal colony-forming units, 98% reduction in aerobic bacteria, and a 66% decrease in C auris.

There has been an emergence of extracorporeal membrane oxygenation-associated infections. Here is a review of how to define them and clinical management of this heterogeneous syndrome.